Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

NO_LONGER_AVAILABLE

Conditions studied: Liver Diseases

In brief

Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood and marrow transplantation. Treatment with currently available (Food and Drug Administration \[FDA\] approved) agents fails in most cases. Recently conducted clinical studies indicate that patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed not with a research intent, but rather to ensure that defibrotide is used by the blood and marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a safe, effective and ethical manner.

Key facts

Study ID

NCT00263978

Run by

Emory University

Starts

2005-11-01

Expected to finish

2009-06-01

Last updated by the study team

2014-07-01

Who can join

Age: 1 and older, up to 22. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Veno-occlusive disease of the liver

Where it is running

• Children's Healthcare of Atlanta — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.